Xilio - XLO Sotuvning operatsion marjasi

Xilio Therapeutics Inc (XLO) kompaniyasining korporativ logotipi

Xilio Therapeutics, Inc. (XLO) uzoq muddatli ustunlikni ta'minlash uchun patentlar bilan himoyalangan maqsadli onkologik dori vositalarini ishlab chiqadi. Operatsion daromadning tushumga nisbati foyda dinamikasini aks ettiradi, bunda -74.90 ko'rsatkichi maqsadli daraja vazifasini o'taydi. Kompaniya daromadlilikni saqlab qolish uchun transchegaraviy xomashyo ta'minotini optimallashtirmoqda. Biroq, hozirda likvidlik klinik sinovlarga yo'naltirilmoqda, bu esa vaqtincha salbiy erkin pul oqimini keltirib chiqarmoqda.

XLO: Xilio Therapeutics Inc Operatsion foyda normasi 04.07.2022 - 20.11.2026

Xilio Therapeutics Inc - tahliliy kesimlar va asosiy koʻrsatkichlar (XLO)

- emitentning bozor qiymati haqida ma'lumotlar:
Kompaniyaning asosiy tahlili:XLO, xiliotx.com
Xilio Therapeutics asosiy tovari

Xilio Therapeutics, Inc. (XLO) kompaniyasining mahalliy ta'sir ko'rsatuvchi onkologik dori vositalarini ishlab chiqishdagi R&D sikli xususiyatlari immun molekulalari uchun mo'ljallangan geografik aktivatsiya platformasining yuqori kapital intensivligini belgilaydi. Moliyaviy xarajatlar va soliqlardan oldingi asosiy biznesdan olingan foyda ulushini aks ettiruvchi operatsion marja ichki xarajatlarni boshqarish samaradorligini baholash imkonini beradi, operatsion marjadagi tebranishlar esa kapitalning bozor risklariga nisbatan fundamental barqarorligining ko'rsatkichi bo'lib xizmat qiladi.

Xilio Therapeutics, Inc. kimlar bilan raqobatlashadi

Operatsion rentabellik BeiGene Ltd|Halozyme Therapeutics - Operatsion foyda marjasi|Sotuvning operatsion marjasi RVMD (Revolution Medicines Corp)|Operatsion foyda koeffitsiyenti AAPG|Operatsion rentabellik CG Oncology Therapeutics CGON|Operatsion foyda normasi URGN|BCAX: Sotuvning operatsion marjasi|PSNL: Operatsion rentabellik|Erasca (ERAS) - Operatsion rentabellik|DCTH - Operatsion faoliyat rentabelligi|YMAB (Y-mAbs Corp) - Operatsion marja|Sotuvning operatsion marjasi Aura Biosciences (AURA)|Operatsion rentabellik Candel Therapeutics Inc. (CADL)|Sotuvning operatsion marjasi Accuray, Inc. ARAY|Operatsion rentabellik sellaslifesciences.com SLS|Operatsion foyda normasi ACTU|CTOR - Operatsion rentabellik|Operatsion faoliyat rentabelligi tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Operatsion rentabellik|FATE: Operatsion foyda koeffitsiyenti|WHWK (Aadi Bioscience, Inc.) - Operatsion marja|TCRX (TScan Therapeutics) - Operatsion foyda koeffitsiyenti|Operatsion rentabellik Champions Oncology (CSBR)|Operatsion faoliyat rentabelligi XBiotech USA|Operatsion rentabellik CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Sotuvning operatsion rentabelligi|RADX - Operatsion rentabellik|ARTV - Operatsion marja|Adlai Nortye Ltd (ANL) - Operatsion rentabellik|Veru Pharma - Operatsion foyda normasi|Operatsion rentabellik Tempest Therapeutics Corp|Operatsion foyda bo'yicha sotuv rentabelligi RENB (Renovaro Inc.)|Operatsion rentabellik Mural Oncology PLC (MURA)|Operatsion marja Kairos Pharma (KAPA)|Operatsion rentabellik onkuretherapeutics.com OKUR|GDTC: Operatsion foyda bo'yicha sotuv rentabelligi|CRIS: Sotuvning operatsion marjasi|apollomicsinc.com (APLM) - Sotuvning operatsion marjasi|THAR: Operatsion marja|Sotuvning operatsion marjasi Advanced Biomed Inc.|Sotuvning operatsion marjasi GNPX|Operatsion foyda bo'yicha sotuv rentabelligi CLDI (Calidi Biotherapeutics)|Operatsion marja SBFM|Xenetic Biosciences, Inc. - Operatsion foyda bo'yicha sotuv rentabelligi|Operatsion rentabellik Salarius Pharmaceuticals SLRX|Operatsion marja purple-biotech.com PPBT|AONC - Operatsion rentabellik|BGNE: Operatsion rentabellik|CKPT: Operatsion marja|Elevation Oncology - Operatsion foyda normasi|ICAD (iCAD) - Operatsion marja|IKNA: Operatsion foyda normasi|Operatsion rentabellik Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operatsion foyda normasi|Operatsion rentabellik MorphoSys Corporation MOR|NAYA: Operatsion foyda bo'yicha sotuv rentabelligi|Ascentage Pharma Group International - Operatsion marja